Studies presented at the American Academy of Neurology meeting confirm nVNS is stimulating the vagus nerve non-invasively and that nVNS can be effective in preventing menstrual migraine• The clinical study shows that non-invasive vagus nerve stimulation (nVNS) with gammaCore reduces the number of monthly headache days for patients with menstrual related migraine by more than a third
• The second study confirms that nVNS is effective in activating afferent (towards the brain) fibers in the vagus nerve in humans.
BASKING RIDGE, N.J: The study presented at the AAN meeting in Vancouver1 this week reported success in an open label study of 56 patients with menstrual migraine using nVNS. Menstrual migraine is one the most common causes of migraine in women and their attacks are typically longer lasting, more disabling, and less responsive to medications than non-menstrual migraine attacks. GammaCore not only reduced the average number of monthly migraine days by 35% (average of 7.2 per monthly cycle to 4.7), but also reduced the average pain intensity experienced, and thus also reduced the average use of rescue/analgesic medications used to treat the attacks per month by 38%.
“nVNS is an effective, safe, and well-tolerated treatment that reduced the number of headache days and use of acute rescue medication in women with menstrual and menstrually-related migraine in our study. GammaCore, which is self-administered by the patient, is portable, easy to use, and without any of the significant side effects of existing medications” commented Dr. Grazzi from the Headache Centre at the Carlo Besta Neurological Institute in Milan, Italy, who presented the study.
The other study, which was carried out in twelve healthy subjects, was presented by Professor Jean Schoenen of the Headache Research Unit at the University of Liege in Belgium, and showed that the targeted fibers in the vagus nerve presumed to be stimulated by the gammaCore nVNS device are in fact activated as previously expected. Prof. Schoenen commented, “This study provides strong evidence that nVNS stimulates afferent vagus nerve fibers [those going to the brain] non-invasively in humans.”
This research furthers the ongoing exploration of the benefits of treatment with nVNS, which has a well-established safety and tolerability profile. This is especially valuable in menstrual and menstrually-related migraine, as studies of pharmaceutical products have produced concerns regarding side effects in women of child-bearing years, drug-drug interactions, and acute medication overuse, which can exacerbate the frequency of migraine attacks. Since gammaCore is convenient and portable it removes two major barriers to the adoption of current VNS delivery devices: the expense (around $30,000) and the requirement to undergo a surgical procedure with the associated risks and side effects of surgery.
1 The 68th American Academy of Neurology Annual Meeting in Vancouver - 15th to 21st April.
electroCore LLC, the New Jersey based bioelectric pharma company, is focused on developing non-invasive vagus nerve stimulation therapies (the gammaCore device) for the treatment of multiple conditions in neurology, psychiatry, gastroenterology, and respiratory fields. The company’s initial target is the treatment of primary headaches (migraine and cluster headache), and the associated chronic co-morbidities of gastric motility, psychiatric, sleep, and pain disorders that drive disproportionately large direct and indirect costs within the healthcare system and society.
Vane Percy & Roberts
Robert Denholm House
Surrey, RH1 4HW
Simon Vane Percy
Vane Percy & Roberts
(T) +44 (0) 1737 821890
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Studies presented at the American Academy of Neurology meeting confirm nVNS is stimulating the vagus nerve non-invasively and that nVNS can be effective in preventing menstrual migraine here
News-ID: 333762 • Views: 463
More Releases from electroCore
GammaCore is both effective and cost effective for the treatment of cluster head …
BASKING RIDGE, N.J: A paper in the Journal of Headache and Pain reports that non-invasive stimulation of the vagus nerve (nVNS) is a cost effective therapy for cluster headache. These findings were based on reductions in medication use and improvements in quality of life. The publication also notes that further economic benefits would have been found had reduced visits to clinics been taken into account. Cluster headache, which
More Releases for VNS
Vagus Nerve Stimulation (VNS) Market Trends, Size, Share, Company Overview, Grow …
Global Vagus Nerve Stimulation (VNS) Market Analysis 2026 Report provides strategists, marketers and senior management with the critical information they need to assess the global Vagus Nerve Stimulation (VNS) Market as it emerges from the Covid-19 shut down. The impact of Coronavirus (COVID-19) on global market has reinforced many trends already shaping the industry pre COVID-19, There is a long-term trend towards the repositioning of players as entertainment providers on
Vagus Nerve Stimulation (VNS) Devices Market Latest Innovations, Drivers and Ind …
Precision Business Insights published a research report on “Vagus Nerve Stimulation (VNS) Devices Market by Product Type (Implantable VNS Devices and External VNS Devices), By Application (Depression, Epilepsy, and Migraine), By End User (Hospitals, Ambulatory Surgical Centers (ASCS), and Others), and Geography- Global/Region/Country Forecast to 2028”. Global vagus nerve stimulation (VNS) devices market was valued at US$ XX Mn in the year 2020 and anticipated to reach at XX%
Vagal Nerve Stimulation (VNS) Market Growth by Top Companies, Trends by Types an …
The vagal nerve stimulation (VNS) market is expected to register a CAGR of 10.30% during the forecast period of 2020 to 2027. MRFR recognizes the following companies as the key players in the global vagal nerve stimulation (VNS)market—LivaNova, PLC (UK), ReShape Lifesciences Inc (US), ElectroCore Medical LLC (US), Boston Scientific Corporation (US), NeuroMetrix, Inc. (US), ImThera Medical, Inc. (US), Inspire Medical Systems, Inc (US), Parasym Ltd (UK), andInnovative Health Solutions, Inc.
Vagus Nerve Stimulation (VNS) Devices Market Growth, Opportunities, Industry App …
LOS ANGELES, United States: The research study offers powerful guidelines for market players to compete well against other participants operating in the global Vagus Nerve Stimulation (VNS) Devices market. It brings to light crucial market dynamics including drivers, challenges, restraints, trends, and opportunities. Readers are provided with detailed qualitative and quantitative analysis, PESTLE analysis, absolute dollar opportunity analysis, and Porter’s Five Forces analysis that focus on various aspects of the
Vagus Nerve Stimulation(VNS) Market Advancement in Medical Sector 2020- LivaNova …
The report begins with the overview of the Vagus Nerve Stimulation(VNS) Market and offers throughout development. It presents a comprehensive analysis of all the regional and major player segments that gives closer insights upon present market conditions and future market opportunities along with drivers, trending segments, consumer behaviour, pricing factors and market performance and estimation. The forecast market information, SWOT analysis, Vagus Nerve Stimulation(VNS) market scenario, and feasibility study are
Vagus Nerve Stimulation (VNS) Devices Market to Witness Robust Expansion by 2024
LP INFORMATION offers a latest published report on Vagus Nerve Stimulation (VNS) Devices Market Analysis and Forecast 2019-2024 delivering key insights and providing a competitive advantage to clients through a detailed report. According to this study, over the next five years the Vagus Nerve Stimulation (VNS) Devices market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from